Core Viewpoint - Guangzheng Eye Hospital (002524.SZ) forecasts a net profit loss of 3 million to 5 million yuan for the year 2025, a significant improvement compared to a loss of 175 million yuan in the same period last year [1]. Financial Performance Summary - The net profit attributable to shareholders is expected to be between -5 million and -3 million yuan, showing a 97.14% improvement compared to the previous year's loss of 174.65 million yuan [2]. - The net profit after deducting non-recurring gains and losses is projected to be between -18 million and -12 million yuan, reflecting a 90.75% increase from last year's loss of 194.52 million yuan [2]. - Basic earnings per share are estimated at -0.0099 yuan, compared to -0.0050 yuan in the previous year [2].

Financial Performance - The company expects a net profit in the range of -5,000 to -3,000 thousand yuan, representing a year-on-year increase of 97.14% to 98.28% compared to the previous year's net profit of -17,465.34 thousand yuan[5]. - The net profit after deducting non-recurring gains and losses is projected to be between -18,000 and -12,000 thousand yuan, showing a year-on-year increase of 90.75% to 93.83% from -19,452.68 thousand yuan in the same period last year[5]. - The basic earnings per share are expected to be between -0.0099 and -0.0050 yuan, compared to -0.34 yuan in the previous year[5]. Operational Management - The company has implemented lean operational management in its medical sector, enhancing operational efficiency through process optimization and cost control measures[7]. - The company anticipates a significant reduction in goodwill impairment compared to 2024, where the impairment provision was 13,463.26 thousand yuan[8]. Earnings Forecast - The financial data presented is preliminary and has not yet been audited by the accounting firm, but there are no significant discrepancies reported[6]. - The company emphasizes the importance of cautious decision-making for investors due to the preliminary nature of the earnings forecast[9]. - The earnings forecast period is from January 1, 2025, to December 31, 2025[3]. - The company has communicated with the accounting firm regarding significant matters related to the earnings forecast[6]. Incentive Plan - The company did not meet the performance assessment trigger values for the 2023 restricted stock incentive plan for the year 2025, leading to a reversal of previously accrued share-based payment expenses[7].

Market Overview - The medical services sector experienced a decline of 1.64% on January 28, with Guangzheng Eye Care leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] Individual Stock Performance - Guangzheng Eye Care (002524) saw a significant drop of 8.63%, closing at 5.08, with a trading volume of 1.41 million shares and a transaction value of 721 million [2] - Other notable declines included Yinuosi (688710) down 7.45% and Haoyuan Pharmaceutical (688131) down 6.49% [2] - In contrast, ST Zhongzhu (600568) increased by 1.43%, closing at 2.83, with a trading volume of 338,300 shares [1] Capital Flow Analysis - The medical services sector experienced a net outflow of 1.697 billion in institutional funds, while retail investors saw a net inflow of 1.544 billion [2] - Notable stocks with significant capital inflow included Sunshine Nuohe (688621) with a net inflow of 27.668 million from institutional investors [3] - Conversely, stocks like ST Zhongzhu (600568) and Wanbang Medical (301520) faced net outflows from institutional investors [3]

Core Viewpoint - Guangzheng Eye Hospital announced that its stock price experienced a cumulative deviation of over 20% on January 26 and January 27, 2026, which meets the criteria for abnormal stock fluctuations set by the Shenzhen Stock Exchange [1]. Group 1 - The stock price fluctuation occurred over two consecutive trading days [1].

Core Viewpoint - The stock of Guangzheng Eye Hospital experienced a significant price fluctuation, with a cumulative increase of over 20% in closing prices over two consecutive trading days, prompting an announcement regarding abnormal stock trading behavior [1] Summary by Relevant Sections - **Stock Price Movement** - The stock price of Guangzheng Eye Hospital rose by more than 20% over two trading days on January 26 and January 27, 2026, indicating a significant deviation from normal trading patterns [1] - **Company Disclosure** - The company confirmed that there are no corrections or supplements needed for previously disclosed information, and no undisclosed significant information has been found that could impact stock trading prices [1] - **Operational Status** - The recent operational situation of the company remains normal, with no significant changes in the internal or external business environment [1] - **Shareholder Activity** - The company, its controlling shareholders, and actual controllers have not engaged in any stock trading activities during the period of abnormal price fluctuation, and there are no undisclosed significant matters [1]

光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2026-002 光正眼科医院集团股份有限公司 关于公司股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 光正眼科医院集团股份有限公司(以下简称"公司"或"本公司")股票（证 券简称：光正眼科，证券代码：002524）于 2026 年 1 月 26 日、2026 年 1 月 27 日连续两个交易日收盘价格涨幅偏离值累计超过 20%，符合深圳证券交易所股票 异常波动的相关标准。 二、公司关注并核实的情况说明 针对公司股票交易异常波动的相关情况，公司对相关事项进行核查，并询问 了公司控股股东，现就有关关注问题及核实结论说明如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、公司未发现近期公共媒体报道了可能或已经对公司股票交易价格产生较 大影响的未公开重大信息； 3、公司近期经营情况正常，内外部经营环境未发生重大变化； 4、公司、控股股东、实际控制人不存在关于公司的应披露而未披露的重大 事项； 5、控股股东、实际控制人在 ...

Market Overview - The medical services sector experienced a decline of 1.41% on January 26, with Meidisi leading the drop [1] - The Shanghai Composite Index closed at 4132.61, down 0.09%, while the Shenzhen Component Index closed at 14316.64, down 0.85% [1] Stock Performance - Notable gainers in the medical services sector included: - Guangzheng Eye Hospital (002524) with a closing price of 5.05, up 10.02% on a trading volume of 266,400 shares and a transaction value of 132 million [1] - Lanwei Medical (301060) closed at 12.28, up 3.98% with a trading volume of 325,000 shares and a transaction value of 392 million [1] - Major decliners included: - Meidisi (688202) closed at 60.88, down 7.28% with a trading volume of 71,600 shares and a transaction value of 444 million [2] - Meinian Health (002044) closed at 7.26, down 6.08% with a trading volume of 3.7675 million shares and a transaction value of 2.776 billion [2] Capital Flow - The medical services sector saw a net outflow of 1.318 billion from institutional investors, while retail investors had a net inflow of 1.011 billion [2] - The capital flow for specific stocks showed: - Boteng Co. (300363) had a net outflow of 39.83 million from institutional investors [3] - Guangzheng Eye Hospital (002524) had a net inflow of 39.29 million from institutional investors [3] - Lanwei Medical (301060) had a net inflow of 24.71 million from institutional investors [3]

Core Viewpoint - The company, Guangzheng Eye Hospital, confirmed that it does not have any business involvement or investment in Hainan International Commercial Space Launch Co., Ltd. [2] Company Summary - Guangzheng Eye Hospital responded to an investor inquiry on an interactive platform regarding potential investments in Hainan International Commercial Space Launch Co., Ltd. [2]

Market Overview - The medical services sector experienced a decline of 0.25% on January 22, with Chengda Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4122.58, up 0.14%, while the Shenzhen Component Index closed at 14327.05, up 0.5% [1] Stock Performance - Notable gainers in the medical services sector included: - Yinos (688710) with a closing price of 66.35, up 5.96% [1] - Hite Bio (300683) at 30.94, up 4.28% [1] - Puri Eye (301239) at 34.79, up 3.73% [1] - Conversely, significant decliners included: - Chengda Pharmaceutical (301201) at 39.67, down 4.16% [2] - Nanmo Bio (688265) at 48.21, down 3.17% [2] - Pruis (301257) at 66.99, down 2.63% [2] Capital Flow - The medical services sector saw a net outflow of 313 million yuan from institutional investors, while retail investors experienced a net inflow of 89.45 million yuan [2] - The capital flow for specific stocks showed: - Innovation Medical (002173) had a net inflow of 89.74 million yuan from institutional investors [3] - Kanglong Chemical (300759) saw a net inflow of 44.95 million yuan from institutional investors [3] - Chengda Pharmaceutical (301201) had a net outflow of 20.46 million yuan from retail investors [3]

Core Viewpoint - The medical services sector experienced a decline of 1.45% on January 19, with Chengdu Xian Dao leading the drop. The Shanghai Composite Index rose by 0.29%, while the Shenzhen Component Index increased by 0.09% [1]. Group 1: Market Performance - The medical services sector saw a significant outflow of 1.45%, with Chengdu Xian Dao's stock price falling by 6.82% to 32.80 [2]. - Major stocks in the medical services sector included New Mileage, which rose by 9.83% to 2.57, and ST Biological, which increased by 5.06% to 8.93 [1][2]. - The total net outflow of main funds in the medical services sector was 1.983 billion, while retail investors saw a net inflow of 1.942 billion [2][3]. Group 2: Individual Stock Performance - New Mileage had a closing price of 2.57 with a trading volume of 3.1192 million shares, resulting in a transaction amount of 778 million [1]. - Chengdu Xian Dao, despite leading the decline, had a trading volume of 292,200 shares and a transaction amount of 976 million [2]. - The stock performance varied significantly, with some stocks like ST Biological and Huazhong Medical showing positive movements, while others like Chengdu Xian Dao and Meinian Health faced notable declines [2][3].